Stijn E Verleden1, Naoya Tanabe2, John E McDonough1, Dragoş M Vasilescu3, Feng Xu3, Wim A Wuyts1, Davide Piloni4, Laurens De Sadeleer1, Stijn Willems1, Cindy Mai5, Jeroen Hostens6, Joel D Cooper7, Erik K Verbeken1, Johny Verschakelen5, Craig J Galban8, Dirk E Van Raemdonck1, Thomas V Colby9, Marc Decramer1, Geert M Verleden1, Naftali Kaminski10, Tillie-Louise Hackett3, Bart M Vanaudenaerde1, James C Hogg11. 1. Department of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium. 2. University of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 3. University of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada. 4. Department of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium; The Respiratory Disease Unit, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. 5. Department of Radiology, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium. 6. The Bruker microCT, Kontich, Belgium. 7. Department of Thoracic Surgery University of Pennsylvania, Philadelphia, PA, USA. 8. Department of Radiology, University of Michigan, Ann Arbor, MI, USA. 9. Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA. 10. Section of Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CT, USA. 11. University of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada. Electronic address: jim.hogg@hli.ubc.ca.
Abstract
BACKGROUND: The observation that patients with idiopathic pulmonary fibrosis (IPF) can have higher than normal expiratory flow rates at low lung volumes led to the conclusion that the airways are spared in IPF. This study aimed to re-examine the hypothesis that airways are spared in IPF using a multiresolution imaging protocol that combines multidetector CT (MDCT), with micro-CT and histology. METHODS: This was a retrospective cohort study comparing explanted lungs from patients with severe IPF treated by lung transplantation with a cohort of unused donor (control) lungs. The donor control lungs had no known lung disease, comorbidities, or structural lung injury, and were deemed appropriate for transplantation on review of the clinical files. The diagnosis of IPF in the lungs from patients was established by a multidisciplinary consensus committee according to existing guidelines, and was confirmed by video-assisted thoracic surgical biopsy or by pathological examination of the contralateral lung. The control and IPF groups were matched for age, sex, height, and bodyweight. Samples of lung tissue were compared using the multiresolution imaging approach: a cascade of clinical MDCT, micro-CT, and histological imaging. We did two experiments: in experiment 1, all the lungs were randomly sampled; in experiment 2, samples were selected from regions of minimal and established fibrosis. The patients and donors were recruited from the Katholieke Universiteit Leuven (Leuven, Belgium) and the University of Pennsylvania Hospital (Philadelphia, PA, USA). The study took place at the Katholieke Universiteit Leuven, and the University of British Columbia (Vancouver, BC, Canada). FINDINGS: Between Oct 5, 2009, and July 22, 2016, explanted lungs from patients with severe IPF (n=11), were compared with a cohort of unused donor (control) lungs (n=10), providing 240 samples of lung tissue for comparison using the multiresolution imaging approach. The MDCT specimen scans show that the number of visible airways located between the ninth generation (control 69 [SD 22] versus patients with IPF 105 [33], p=0·0023) and 14th generation (control 9 [6] versus patients with IPF 49 [28], p<0·0001) of airway branching are increased in patients with IPF, which we show by micro-CT is due to thickening of their walls and distortion of their lumens. The micro-CT analysis showed that compared with healthy (control) lung anatomy (mean 5·6 terminal bronchioles per mL [SD 1·6]), minimal fibrosis in IPF tissue was associated with a 57% loss of the terminal bronchioles (mean 2·4 terminal bronchioles per mL [SD 1·0]; p<0·0001), the appearance of fibroblastic foci, and infiltration of the tissue by inflammatory immune cells capable of forming lymphoid follicles. Established fibrosis in IPF tissue had a similar reduction (66%) in the number of terminal bronchioles (mean 1·9 terminal bronchioles per mL [SD 1·4]; p<0·0001) and was dominated by increased airspace size, Ashcroft fibrosis score, and volume fractions of tissue and collagen. INTERPRETATION: Small airways disease is a feature of IPF, with significant loss of terminal bronchioles occuring within regions of minimal fibrosis. On the basis of these findings, we postulate that the small airways could become a potential therapeutic target in IPF. FUNDING: Katholieke Universiteit Leuven, US National Institutes of Health, BC Lung Association, and Genentech.
BACKGROUND: The observation that patients with idiopathic pulmonary fibrosis (IPF) can have higher than normal expiratory flow rates at low lung volumes led to the conclusion that the airways are spared in IPF. This study aimed to re-examine the hypothesis that airways are spared in IPF using a multiresolution imaging protocol that combines multidetector CT (MDCT), with micro-CT and histology. METHODS: This was a retrospective cohort study comparing explanted lungs from patients with severe IPF treated by lung transplantation with a cohort of unused donor (control) lungs. The donor control lungs had no known lung disease, comorbidities, or structural lung injury, and were deemed appropriate for transplantation on review of the clinical files. The diagnosis of IPF in the lungs from patients was established by a multidisciplinary consensus committee according to existing guidelines, and was confirmed by video-assisted thoracic surgical biopsy or by pathological examination of the contralateral lung. The control and IPF groups were matched for age, sex, height, and bodyweight. Samples of lung tissue were compared using the multiresolution imaging approach: a cascade of clinical MDCT, micro-CT, and histological imaging. We did two experiments: in experiment 1, all the lungs were randomly sampled; in experiment 2, samples were selected from regions of minimal and established fibrosis. The patients and donors were recruited from the Katholieke Universiteit Leuven (Leuven, Belgium) and the University of Pennsylvania Hospital (Philadelphia, PA, USA). The study took place at the Katholieke Universiteit Leuven, and the University of British Columbia (Vancouver, BC, Canada). FINDINGS: Between Oct 5, 2009, and July 22, 2016, explanted lungs from patients with severe IPF (n=11), were compared with a cohort of unused donor (control) lungs (n=10), providing 240 samples of lung tissue for comparison using the multiresolution imaging approach. The MDCT specimen scans show that the number of visible airways located between the ninth generation (control 69 [SD 22] versus patients with IPF 105 [33], p=0·0023) and 14th generation (control 9 [6] versus patients with IPF 49 [28], p<0·0001) of airway branching are increased in patients with IPF, which we show by micro-CT is due to thickening of their walls and distortion of their lumens. The micro-CT analysis showed that compared with healthy (control) lung anatomy (mean 5·6 terminal bronchioles per mL [SD 1·6]), minimal fibrosis in IPF tissue was associated with a 57% loss of the terminal bronchioles (mean 2·4 terminal bronchioles per mL [SD 1·0]; p<0·0001), the appearance of fibroblastic foci, and infiltration of the tissue by inflammatory immune cells capable of forming lymphoid follicles. Established fibrosis in IPF tissue had a similar reduction (66%) in the number of terminal bronchioles (mean 1·9 terminal bronchioles per mL [SD 1·4]; p<0·0001) and was dominated by increased airspace size, Ashcroft fibrosis score, and volume fractions of tissue and collagen. INTERPRETATION:Small airways disease is a feature of IPF, with significant loss of terminal bronchioles occuring within regions of minimal fibrosis. On the basis of these findings, we postulate that the small airways could become a potential therapeutic target in IPF. FUNDING: Katholieke Universiteit Leuven, US National Institutes of Health, BC Lung Association, and Genentech.
Authors: H O Coxson; J C Hogg; J R Mayo; H Behzad; K P Whittall; D A Schwartz; P G Hartley; J R Galvin; J S Wilson; G W Hunninghake Journal: Am J Respir Crit Care Med Date: 1997-05 Impact factor: 21.405
Authors: Dragoş M Vasilescu; André B Phillion; Naoya Tanabe; Daisuke Kinose; David F Paige; Jacob J Kantrowitz; Gang Liu; Hanqiao Liu; Nick Fishbane; Stijn E Verleden; Bart M Vanaudenaerde; Marc Lenburg; Christopher S Stevenson; Avrum Spira; Joel D Cooper; Tillie-Louise Hackett; James C Hogg Journal: J Appl Physiol (1985) Date: 2016-11-17
Authors: Dragos M Vasilescu; Christine Klinge; Lars Knudsen; Leilei Yin; Ge Wang; Ewald R Weibel; Matthias Ochs; Eric A Hoffman Journal: J Appl Physiol (1985) Date: 2012-12-20
Authors: Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois Journal: Lancet Date: 2011-05-13 Impact factor: 79.321
Authors: Stijn E Verleden; Dragoş M Vasilescu; Stijn Willems; David Ruttens; Robin Vos; Elly Vandermeulen; Jeroen Hostens; John E McDonough; Erik K Verbeken; Johny Verschakelen; Dirk E Van Raemdonck; Benoît Rondelet; Christiane Knoop; Marc Decramer; Joel Cooper; James C Hogg; Geert M Verleden; Bart M Vanaudenaerde Journal: Am J Respir Crit Care Med Date: 2014-02-01 Impact factor: 21.405
Authors: Stijn E Verleden; Dragoş M Vasilescu; John E McDonough; David Ruttens; Robin Vos; Elly Vandermeulen; Hannelore Bellon; Rachel Geenens; Erik K Verbeken; Johny Verschakelen; Dirk E Van Raemdonck; Wim A Wuyts; Youri Sokolow; Christiane Knoop; Joel D Cooper; James C Hogg; Geert M Verleden; Bart M Vanaudenaerde Journal: Eur Respir J Date: 2015-06-25 Impact factor: 16.671
Authors: John E McDonough; Ren Yuan; Masaru Suzuki; Nazgol Seyednejad; W Mark Elliott; Pablo G Sanchez; Alexander C Wright; Warren B Gefter; Leslie Litzky; Harvey O Coxson; Peter D Paré; Don D Sin; Richard A Pierce; Jason C Woods; Annette M McWilliams; John R Mayo; Stephen C Lam; Joel D Cooper; James C Hogg Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Naoya Tanabe; Dragoş M Vasilescu; John E McDonough; Daisuke Kinose; Masaru Suzuki; Joel D Cooper; Peter D Paré; James C Hogg Journal: Am J Respir Crit Care Med Date: 2017-03-01 Impact factor: 21.405
Authors: Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake Journal: JAMA Date: 2016-02-16 Impact factor: 56.272
Authors: James C Hogg; Fanny Chu; Soraya Utokaparch; Ryan Woods; W Mark Elliott; Liliana Buzatu; Ruben M Cherniack; Robert M Rogers; Frank C Sciurba; Harvey O Coxson; Peter D Paré Journal: N Engl J Med Date: 2004-06-24 Impact factor: 91.245
Authors: Preetish Kadur Lakshminarasimha Murthy; Vishwaraj Sontake; Aleksandra Tata; Yoshihiko Kobayashi; Lauren Macadlo; Kenichi Okuda; Ansley S Conchola; Satoko Nakano; Simon Gregory; Lisa A Miller; Jason R Spence; John F Engelhardt; Richard C Boucher; Jason R Rock; Scott H Randell; Purushothama Rao Tata Journal: Nature Date: 2022-03-30 Impact factor: 69.504
Authors: Laurens J De Sadeleer; John E McDonough; Jonas C Schupp; Xiting Yan; Arno Vanstapel; Anke Van Herck; Stephanie Everaerts; Vincent Geudens; Annelore Sacreas; Tinne Goos; Celine Aelbrecht; Tim S Nawrot; Dries S Martens; Dominique Schols; Sandra Claes; Johny A Verschakelen; Eric K Verbeken; Maximilian Ackermann; Anabelle Decottignies; Manon Mahieu; Tillie-Louise Hackett; James C Hogg; Bart M Vanaudenaerde; Stijn E Verleden; Naftali Kaminski; Wim A Wuyts Journal: Am J Respir Crit Care Med Date: 2022-01-01 Impact factor: 21.405
Authors: Paolo Spagnolo; Jonathan A Kropski; Mark G Jones; Joyce S Lee; Giulio Rossi; Theodoros Karampitsakos; Toby M Maher; Argyrios Tzouvelekis; Christopher J Ryerson Journal: Pharmacol Ther Date: 2020-12-24 Impact factor: 13.400
Authors: Paul Reynaud; Engi Ahmed; Isabelle Serre; Lucie Knabe; Sébastien Bommart; Carey Suehs; Isabelle Vachier; Jean Philippe Berthet; Micaela Romagnoli; Charlotte Vernisse; Jean Pierre Mallet; Anne Sophie Gamez; Arnaud Bourdin Journal: Front Immunol Date: 2021-02-26 Impact factor: 7.561
Authors: Ian T Stancil; Jacob E Michalski; Duncan Davis-Hall; Hong Wei Chu; Jin-Ah Park; Chelsea M Magin; Ivana V Yang; Bradford J Smith; Evgenia Dobrinskikh; David A Schwartz Journal: Nat Commun Date: 2021-07-27 Impact factor: 17.694